and pharmaceutical companies to design new useful chemical entities and to evaluate their adverse effects and environmental impact at an early stage of development. The data for many of their expert systems have been developed by the US Food and Drug Administration CDER office and is used by many government regulatory agencies such as US, Canadian, Japan, Danish and the OECD in conjunction with the REACH program.